Diamyd Medical presents clinical data at the BIO CEO & Investor Conference 2009 in New York

Diamyd Medical announces today that Elisabeth Lindner, President and Chief Executive Officer of the company, has been invited to speak at the BIO CEO & Investor Conference in New York on February 9. The presentation will take place at 2.45 pm at the Waldorf Astoria.Diamyd Medical develops pharmaceuticals for treatment of autoimmune diabetes. The worldwide cost for treatment of diabetes and its complications exceeds USD 230 billion per year (International Diabetes Federation). Diamyd Medical’s most advanced project is the diabetes vaccine Diamyd® for treatment of type 1 diabetes. The vaccine